Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Separation Science



View Channel

Microscopy | Image Analysis



View Channel

IT Solutions and Laboratory Automation



View Channel


Conferences | Events

Horizon Enters into Partnership with Pirbright Institute to Support Research into Improvement of Vaccine Yields

publication date: May 11, 2018
author/source: Horizon Discovery

horizon discoveryExtends Horizon’s biomanufacturing capabilities into vaccine manufacture

Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation

Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation to deliver inspired cell solutions, announces that it has extended its biomanufacturing capabilities through an agreement with The Pirbright Institute to jointly work on a research program aimed at deploying cell engineering to increase the yields of livestock vaccines.

The development of efficient and affordable vaccines against viral diseases plays an important role in meeting the rapidly growing demand in the AgBio market, where global production is persistently reduced through viral infection and where the consequences of an outbreak can be devastating.

Horizon will use its expertise in CRISPR/Cas9 gene editing to remove the chIFITM genes in chicken cells, thereby overcoming one of the main barriers for viral replication with the potential to boost the levels of vaccine virus produced between five and ten-fold. Vaccines produced in avian systems represent an approximately $3.4 billion market1. A significant increase in yield may lead to a substantial decrease in manufacturing costs and pricing.  The project is set to run for four years and this new technology could be commercially available by 2021.

Richard Vellacott, Interim CEO and CFO, Horizon Discovery, commented: “As a global leader in the application of gene editing to harness the power of the cell, Horizon is transforming the life sciences both in human biology and beyond.  We are now extending our biomanufacturing expertise into the agriculture market where there is an acute need to protect and improve yields, driven by a rapidly growing global population and increasing environmental pressures. We are pleased to partner with The Pirbright Institute in this project which promises to have a significant impact on vulnerable populations worldwide.”

Dr Mark Fife, research lead and Head of the Genetics and Genomics group, The Pirbright Institute, said: “The increase in yield sought from this project will make vaccines cheaper to produce and more accessible to livestock owners in developing nations. We will first focus on increasing flu vaccine yields, but the technique can be applied to multiple livestock viral diseases and potentially human diseases as well. Once this technique, for which a patent application has been filed, has been successfully piloted, The Pirbright Institute intends to work with commercial partners, such as Horizon Discovery, who will help bring this new technology to market."


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners